Home > Drugs A – Z > Ethambutol (By mouth)

Ethambutol (By mouth)

Treats tuberculosis (TB).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Ethambutol is used to treat tuberculosis (TB). It is used with other medicines for TB. This medicine may also be used for other problems as determined by your doctor. To help clear up your tuberculosis (TB) infection completely, you must keep taking this medicine for the full time of treatment, even if you begin to feel better. This is very important. It is also important that you do not miss any… Read more
Brand names include
Myambutol
Drug classes About this
Antitubercular

What works? Research summarized

Evidence reviews

Value of diagnostic tests for the ethambutol resistance in Mycobacterium tuberculosis: a systematic review

Bibliographic details: Zhang ZM, Zhang ZJ, Li PJ, Yang KH, Zhu BD.  Value of diagnostic tests for the ethambutol resistance in Mycobacterium tuberculosis: a systematic review. Chinese Journal of Evidence-Based Medicine 2010; 10(12): 1456-1460

Anti‐tuberculous therapy for maintaining remission in Crohn's disease

Tuberculous bacteria have been suggested as a possible cause of Crohn's disease due to a similarity between Crohn's and tuberculous lesions when viewed under a microscope. Four studies examined the use of anti‐tuberculous therapy to reduce the chance of the disease recurring in patients with non‐active Crohn's disease. The results of these studies suggest that this treatment might be effective for this purpose. However, this finding has not been definitively proven, and anti‐tuberculous therapy should not be used to treat Crohn's disease without further study.

Nitrate reductase assay for rapid detection of isoniazid, rifampicin, ethambutol and streptomycin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis

Colorimetric phenotypic tests recently gained interest because traditional primary drug susceptibility testing of Mycobacterium tuberculosis isolates takes a long time. We used meta-analysis techniques to review the reliability and accuracy of the nitrate reductase assay (NRA), which is one of the most popular colorimetric methods to detect resistance to first-line drugs. Medline, PubMed, ISI Web, Web of Science, and Google Scholar were used to search for studies enrolled in the meta-analysis. The analysis included 35 studies for isoniazid (INH), 38 for rifampin (RIF), and 22 for ethambutol (EMB) and streptomycin (STR). Summary receiver operating characteristic (SROC) curves were applied to summarize diagnostic accuracy. The meta-analyses were performed by the use of Meta-DiSc software (version 1.4) and were focused on sensitivity and specificity values for measurements of accuracy. The pooled sensitivities were 96% for INH, 97% for RIF, 90% for EMB, and 82% for STR. The pooled specificities for INH, RIF, EMB, and STR were 99%, 100%, 98%, and 96%, respectively. The times required to obtain results were between 5 and 28 days by the direct NRA and between 5 and 14 days by the indirect test. In conclusion, the present meta-analysis showed that the NRA is a reliable low-cost rapid colorimetric susceptibility test that can be used for the detection of multidrug-resistant (MDR) tuberculosis, including detection of EMB resistance. However, the test appears to have a relatively low sensitivity for STR and needs further improvement.

See all (22)

Summaries for consumers

Anti‐tuberculous therapy for maintaining remission in Crohn's disease

Tuberculous bacteria have been suggested as a possible cause of Crohn's disease due to a similarity between Crohn's and tuberculous lesions when viewed under a microscope. Four studies examined the use of anti‐tuberculous therapy to reduce the chance of the disease recurring in patients with non‐active Crohn's disease. The results of these studies suggest that this treatment might be effective for this purpose. However, this finding has not been definitively proven, and anti‐tuberculous therapy should not be used to treat Crohn's disease without further study.

Six‐month therapy for people with abdominal tuberculosis

Abdominal tuberculosis (TB) is a type of TB that affects the gut, the peritoneum (the lining of the abdominal cavity), abdominal lymph nodes, and, more rarely, the solid organs in the abdomen (liver, pancreas, and spleen). Abdominal TB leads to severe illness in adults and children, and can cause complications, such as bowel rupture, which can lead to death.

Substituting or adding fluoroquinolones to established first‐line antituberculous drug regimens gives no additional benefit or risks

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis bacteria. Over two billion people worldwide are believed to be latently infected with TB and approximately 10% of these people will develop active TB later in life. The World Health Organization currently only recommend treatment with fluoroquinolones for patients who cannot take standard first‐line drugs. In this review, we examined the effect of including fluoroquinolones in first‐line treatment regimens on people with presumed drug‐sensitive tuberculosis.

See all (4)

PubMed Health Blog...

read all...